JAK2 and Chronic Eosinophilic Leukemia, Not Otherwise Specified: Ruxolitinib induced cytogenetic as well as clinical remission in patients with t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia [17–19, 33].